The BEACON Study (Breast Cancer Outcomes With NKTR-102)

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens.

The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nektar Therapeutics
• Treatments: Etirinotecan pegol

Criteria

Inclusion Criteria (major highlights):

• Patient is an adult female with histologically or cytologically confirmed carcinoma of the breast for whom single-agent cytotoxic chemotherapy is indicated

• Patient can have either measurable or non-measurable disease by RECIST.

• Patient has received prior therapy (administered in the neoadjuvant, adjuvant and/or metastatic setting) with an anthracycline, a taxane and capecitabine

• Patient has minimum of 2 and a maximum of 5 prior cytotoxic chemotherapy regimens with the last dose administered within 6 months. A minimum of two chemotherapy regimens had to be for locally recurrent and/or metastatic disease. All therapy received prior to a diagnosis of metastatic disease (eg, neoadjuvant, adjuvant or repeated adjuvant therapy following a second resection) is counted as one regimen.

• Patient has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Adequate hematopoietic, liver and kidney functions.

Exclusion Criteria (major highlights):

• Patient with chemotherapy within 21 days, radiotherapy within 14 days, biological therapy with 14 days, hormonal therapy within 7 days and investigational therapy within 21 days prior to randomization.

• Patient with any major surgery within 28 days prior to randomization.

• Patient with concurrent use of biologic agents for the treatment of cancer including antibodies or any investigational agent(s).

• Patient with prior treatment for cancer with a camptothecin derivative.

• Patient with chronic or acute GI disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care to control diarrhea in the 28 days prior to randomization.

• Patient received pharmacotherapy for hepatitis B or C, tuberculosis or HIV.

• Patient with known cirrhosis diagnosed with Child-PUGH Class A or higher liver disease.

• Patient with prior malignancy (other than breast cancer) except for non-melanoma skin cancer and carcinoma in situ (of the cervix or bladder), unless diagnosed and definitively treated more than 5 years prior to randomization.

• Patient requiring daily use of oxygen supplementation in the 28 days prior to randomization.

• Patients with significant cardiovascular impairment.